DYN:NYE-Dynegy Inc. (USD)

EQUITY | Biotechnology | New York Stock Exchange

Last Closing

USD 33.03

Change

0.00 (0.00)%

Market Cap

USD 1.03B

Volume

1.42M

Analyst Target

USD 10.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dynegy Inc, through its subsidiaries, is engaged in the production and sale of electric energy, capacity and ancillary services in three segments Coal, IPH and Gas. Its sells electric energy from its power generation facilities.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 34.06B
ARGX argenx NV ADR

N/A

USD 32.17B
MRNA Moderna Inc

N/A

USD 26.25B
SMMT Summit Therapeutics PLC

N/A

USD 23.47B
BGNE BeiGene Ltd

N/A

USD 21.94B
RPRX Royalty Pharma Plc

N/A

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 16.16B
UTHR United Therapeutics Corporatio..

N/A

USD 15.09B

ETFs Containing DYN

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 148.35% 96% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 148.35% 95% A 97% N/A
Trailing 12 Months  
Capital Gain 200.82% 96% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 200.82% 96% N/A 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 719.40% 96% N/A 98% N/A
Dividend Return 721.73% 96% N/A 98% N/A
Total Return 2.34% 44% F 53% F
Risk Return Profile  
Volatility (Standard Deviation) 1,691.05% 7% C- 3% F
Risk Adjusted Return 42.68% 90% A- 73% C
Market Capitalization 1.03B 92% A 84% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.27 54% 86%
Price/Book Ratio 5.97 23% 19%
Price / Cash Flow Ratio -17.04 89% 88%
Price/Free Cash Flow Ratio -8.87 89% 87%
Management Effectiveness  
Return on Equity -52.46% 65% 30%
Return on Invested Capital -140.93% 19% 7%
Return on Assets -31.45% 49% 16%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector